Matthew Frohn

Microvisk Ltd. engages in the manufacture and development of micro-viscometer based on micro electro mechanical sensors technology for medical field. The firm's products include CoagMax, CoagLite, CoagManager and SmartStrip. It develops technology for the detection and analysis of a fluid's properties using a cantilever-based micro-viscometer. The company was founded by Vladislav Djakov, Paul Morgan Vernon and Jeremy Burford Peckham in 2004 and is headquartered in Oxford, the United Kingdom.

OrganOx Ltd. develops a medical device for liver transplantation. The firm's product OrganOx metra, is a fully automated normothermic liver perfusion device for improved organ preservation. It also engages in research and development of transplantation related technologies. The company was founded by Peter Friend and Constantin Coussios in April 2008 and is headquartered in Oxford, the United Kingdom.

Longwall Venture Partners LLP (Longwall Ventures) is a venture capital firm founded in 2006. The firm is headquartered in Oxford, the United Kingdom.

Sensiia Ltd. develops consumer telemedicine solutions. Its flagship product, DuoFertility is a stick-on sensor and handheld reader device that tracks specific biometrics like temperature to help women conceive. The firms services combine wearable monitoring that continuously tracks multiple elements of physiological measurement, scientific and medically based data analytics and specialist advisers to provide personalized, positive health outcomes in areas that affect including fertility, sleep disturbance and pain. The company was founded by Shamus Louis Godfrey Husheer, David Naumann, Oriane Elisabeth Chausiaux, Lydia Ferguson, Chafic Ayoub and Scott Robert Mackie in 2006 and is headquartered in Cambridge, the United Kingdom.

OxSonics Ltd. provides treatments to solid tumour cancer patients. Its drug delivery platform, SonoTran, delivers drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. The company also provides on-screen feedback as to where and when drug delivery has taken place, maximizing the potential of complete tumour coverage. OxSonics was founded by Colin Story, Constantin Coussios, Robert Carlisle and Christian Coviello in July 2013 and is headquartered in Oxford, the United Kingdom.

Crysalin Ltd. develops crysalin lattice technology for protein structure determination. Its portfolio includes crysalins, a protein-based nanotechnology for application in protein structure determination, as well as biosensor development and optoelectronics. The company was founded by Martin Noble and John Sinclair in June 2007 and is headquartered in Oxfordshire, the United Kingdom.

Base4 Innovation Ltd. develops single molecule detection platforms for healthcare and life sciences. The firm develops DNA sequencing using techniques based on silicon chip technology which can easily be scaled up and this high-throughput technology will cut the time and cost of genetic tests, enabling them to be used much more in patient diagnosis and treatment. The company was founded by Cameron Alexander Frayling in 2007 and is headquartered in Cambridge, the United Kingdom.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

Caristo Diagnostics Ltd. engages in the development of cardiovascular diagnostic tools. The company was founded by Charalambos Antoniades on June 22, 2018 and is headquartered in Oxford, the United Kingdom.